No Data
Noile-Immune Biotech: Extraordinary Report
Noile-Immune Biotech: Confirmation letter
Noile-Immune Biotech: Financial Report - 10th Term (2024/01/01 - 2024/12/31)
Noil Immune --- For the fiscal year ending December 2024, the in-house drug development business and the joint pipeline will continue to be promoted.
Noil Immune Biotech <4893> announced its financial results for the fiscal year ending December 2024 on the 14th. Business revenue was 0.007 billion yen (compared to 0.316 billion yen in the previous term), operating loss was 1.069 billion yen (compared to a loss of 0.775 billion yen in the previous term), recurring loss was 0.962 billion yen (compared to a loss of 1.127 billion yen in the previous term), and net loss for the year was 0.964 billion yen (compared to a loss of 1.13 billion yen in the previous term). As for the company's business status for the fiscal year, the self-developed drug discovery business based on PRIME technology and the joint pipeline will continue.
Noile-Immune Biotech: Summary of financial results for the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)
Kirin HD, Matsukiyo Cocok, Dentsu Group, Rakuten Group (14th) (1379-5368)
The above Calendar is merely a schedule and is subject to change due to the company's circumstances.--------------------------------------- February 14 (Friday) <1379> Hokuto <1380> Akigawa Boku-en <1417> Mirait-Wan <142A> Jinjibu <1438> Gifu Landscaping <1443> Giken HD <1447> SAAF HD <145A> Elizbee<
